Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,205.89
(
-1.08%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ciotera post# 88617

Wednesday, 01/27/2010 2:28:43 AM

Wednesday, January 27, 2010 2:28:43 AM

Post# of 257580

…I do not agree that the "third agent paradigm" is here to stay indefinitely. Truvada may be the cleanest nuke but there are cleaner classes now, so I wouldn't be surprised to see nuke-sparing regimens come to dominate first line at some point because of improved tolerability.

According to GILD’s 4Q09 CC yesterday, Truvada is used by 81% of Isentress patients and 91% of Prezista patients in the first-line setting. If anything, the Truvada “paradigm” appears to be strengthening rather than weakening as new HIV agents are added to the armamentarium. Regards, Dew


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today